口腔共济失调毛细血管扩张症(ATR)相关抑制剂BAY 1895344的首次人体试验
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose Escalation: Patient enrollment and disposition
Presented By Johann De Bono at 2019 ASCO Annual Meeting
ATR inhibitor BAY 1895344 pharmacokinetic profile
Presented By Johann De Bono at 2019 ASCO Annual Meeting
ATR inhibitor BAY 1895344 PD profile<br />Target modulation of pH2AX and pKAP1 levels in paired tumor biopsies
Conclusions
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Acknowledgments
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose escalation: RECIST / PCWG3 response by patient
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Targeting replication stress and DNA damage repair <br />by ATR inhibition
Presented By Johann De Bono at 2019 ASCO Annual Meeting
BAY 1895344: <br />A highly selective and potent inhibitor of ATR
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors<br />
Presented By Johann De Bono at 2019 ASCO Annual Meeting
MTD determination
Presented By Johann De Bono at 2019 ASCO Annual Meeting
All-cause AEs of grade ≥3 (occurring in ≥18% of patients)
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Clinical case: patient #2
PresAnnual Meeting
Clinical case: patient #3<br />Expansion cohort
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Phase I study design
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose-limiting toxicity criteria
Patient characteristics
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose-escalation schema and MTD determination
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose escalation: durability of response / SD
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Clinical case: patient #1
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose Escalation: Patient enrollment and disposition
Presented By Johann De Bono at 2019 ASCO Annual Meeting
ATR inhibitor BAY 1895344 pharmacokinetic profile
Presented By Johann De Bono at 2019 ASCO Annual Meeting
ATR inhibitor BAY 1895344 PD profile<br />Target modulation of pH2AX and pKAP1 levels in paired tumor biopsies
Conclusions
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Acknowledgments
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose escalation: RECIST / PCWG3 response by patient
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Targeting replication stress and DNA damage repair <br />by ATR inhibition
Presented By Johann De Bono at 2019 ASCO Annual Meeting
BAY 1895344: <br />A highly selective and potent inhibitor of ATR
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors<br />
Presented By Johann De Bono at 2019 ASCO Annual Meeting
MTD determination
Presented By Johann De Bono at 2019 ASCO Annual Meeting
All-cause AEs of grade ≥3 (occurring in ≥18% of patients)
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Clinical case: patient #2
PresAnnual Meeting
Clinical case: patient #3<br />Expansion cohort
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Phase I study design
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose-limiting toxicity criteria
Patient characteristics
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose-escalation schema and MTD determination
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Dose escalation: durability of response / SD
Presented By Johann De Bono at 2019 ASCO Annual Meeting
Clinical case: patient #1
Presented By Johann De Bono at 2019 ASCO Annual Meeting